[
  {
    "ts": null,
    "headline": "Franklin Biotechnology Discovery Fund Q2 2025 Commentary",
    "summary": "Franklin Templetonâs Biotechnology Discovery Fund sees long-term potential despite Q2 losses. Explore how innovation and AI are shaping its outlook.",
    "url": "https://finnhub.io/api/news?id=d61632bb7ac932a66ab21f6c57260f4bb79e88518f44428ce4f279a1392e761e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753997700,
      "headline": "Franklin Biotechnology Discovery Fund Q2 2025 Commentary",
      "id": 136159393,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1408826216/image_1408826216.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Franklin Templetonâs Biotechnology Discovery Fund sees long-term potential despite Q2 losses. Explore how innovation and AI are shaping its outlook.",
      "url": "https://finnhub.io/api/news?id=d61632bb7ac932a66ab21f6c57260f4bb79e88518f44428ce4f279a1392e761e"
    }
  },
  {
    "ts": null,
    "headline": "Trump Talks Tough on Drug Prices but His Demands Have Softened",
    "summary": "The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by late September.",
    "url": "https://finnhub.io/api/news?id=abfd0cbc3bdf5cf7eec493e57c4c23222429aa6d3fbd91ae1cf65b8720b77b7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753997100,
      "headline": "Trump Talks Tough on Drug Prices but His Demands Have Softened",
      "id": 136160929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by late September.",
      "url": "https://finnhub.io/api/news?id=abfd0cbc3bdf5cf7eec493e57c4c23222429aa6d3fbd91ae1cf65b8720b77b7a"
    }
  },
  {
    "ts": null,
    "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
    "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753992991,
      "headline": "What Trump's Big Pharma CEO letters mean for drug pricing power",
      "id": 136160870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "President Trump is turning up the heat on Big Pharma, sending letters to 17 major drugmakers demanding lower prices across their entire portfolios. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to explain how the administration is pushing for most-favored-nation pricing and giving companies until September 29 to comply. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=4833e7f299553f7689706923f0de2bea0e4ca660804c1eee2c139edccb399c18"
    }
  },
  {
    "ts": null,
    "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
    "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
    "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753986626,
      "headline": "Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs",
      "id": 136160873,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "President Trump sent letters to 17 pharmaceutical companies on Thursday asking them to lower costs of drugs for U.S. consumers to the lowest price offered in other developed nations, following up on an executive order issued in May.",
      "url": "https://finnhub.io/api/news?id=6c9fe155402ddc330d8fc8a3f0a9c10084ffc5e5c1b09cdba3c34ed81efc1a64"
    }
  },
  {
    "ts": null,
    "headline": "Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today",
    "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results that beat revenue expectations. The drugmaker trimmed its adjusted earnings per share guidance for 2025, attributing the cut to a $0.57 per share charge from a partnership with BioNTech. This charge also hit second-quarter net income, which fell compared to the prior year. Beyond the one-time charge,",
    "url": "https://finnhub.io/api/news?id=be2158b5954b6b2cd44ea6e89a6bc525408a33069a2e683bb573f93dd2b1dbc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753983641,
      "headline": "Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today",
      "id": 136161221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results that beat revenue expectations. The drugmaker trimmed its adjusted earnings per share guidance for 2025, attributing the cut to a $0.57 per share charge from a partnership with BioNTech. This charge also hit second-quarter net income, which fell compared to the prior year. Beyond the one-time charge,",
      "url": "https://finnhub.io/api/news?id=be2158b5954b6b2cd44ea6e89a6bc525408a33069a2e683bb573f93dd2b1dbc9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=0fecdfd250aa6490b80c1dbc5cf36509fcd3690f007d65eda0cd14c55dc0a9bb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753980060,
      "headline": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
      "id": 136171196,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=0fecdfd250aa6490b80c1dbc5cf36509fcd3690f007d65eda0cd14c55dc0a9bb"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ETCompany ParticipantsAdam Lenkowsky - Executive VP &amp;...",
    "url": "https://finnhub.io/api/news?id=2f66762f994ff0a9676e5234b40d4f6322c557c4d6a067513cc8e28f88639629",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753980059,
      "headline": "Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript",
      "id": 136158450,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ETCompany ParticipantsAdam Lenkowsky - Executive VP &amp;...",
      "url": "https://finnhub.io/api/news?id=2f66762f994ff0a9676e5234b40d4f6322c557c4d6a067513cc8e28f88639629"
    }
  },
  {
    "ts": null,
    "headline": "Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook",
    "summary": "Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm Holdings (ARM) shares slide after the company posted weaker-than-expected guidance, with the CEO confirming plans to begin producing its own chips. AbbVie (ABBV) stock jumps after topping earnings expectations and raising guidance. Bristol-Myers Squibb (BMY) lowered its earnings outlook due to a BioNTech (BNTX) partnership-related charge but lifted revenue guidance on strength across its product portfolio. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=c7c520a2fe0b5295c105057369c7cfca8e4769a250a2c81e4898c10917ce7a6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753978732,
      "headline": "Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook",
      "id": 136155117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm Holdings (ARM) shares slide after the company posted weaker-than-expected guidance, with the CEO confirming plans to begin producing its own chips. AbbVie (ABBV) stock jumps after topping earnings expectations and raising guidance. Bristol-Myers Squibb (BMY) lowered its earnings outlook due to a BioNTech (BNTX) partnership-related charge but lifted revenue guidance on strength across its product portfolio. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=c7c520a2fe0b5295c105057369c7cfca8e4769a250a2c81e4898c10917ce7a6e"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View",
    "summary": "BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.",
    "url": "https://finnhub.io/api/news?id=7923eb4896a0b4806efeb21e3af205575e32016179da94ee7feaa6797471ad63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753976580,
      "headline": "Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View",
      "id": 136155302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.",
      "url": "https://finnhub.io/api/news?id=7923eb4896a0b4806efeb21e3af205575e32016179da94ee7feaa6797471ad63"
    }
  },
  {
    "ts": null,
    "headline": "PCE Comes in Warmer Than Expected",
    "summary": "PCE Comes in Warmer Than Expected.",
    "url": "https://finnhub.io/api/news?id=1ca45a09932eae527f2336d5e09c3507eca1f8ed0fa96a535a7ff1142a8dad69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753974480,
      "headline": "PCE Comes in Warmer Than Expected",
      "id": 136155303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PCE Comes in Warmer Than Expected.",
      "url": "https://finnhub.io/api/news?id=1ca45a09932eae527f2336d5e09c3507eca1f8ed0fa96a535a7ff1142a8dad69"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic",
    "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=9be9b0bd8ba66c53be7e8c95bc33fdc987ec9b97f697513af960e6d2e411c785",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753974118,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic",
      "id": 136155305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company’s full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts’ estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=9be9b0bd8ba66c53be7e8c95bc33fdc987ec9b97f697513af960e6d2e411c785"
    }
  },
  {
    "ts": null,
    "headline": "Economy Heating Up on PCE for June",
    "summary": "Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.",
    "url": "https://finnhub.io/api/news?id=1f9132f77d9ef9cec840390c58ca99a40eb0245409cda9055d2f96c3dd12d452",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753973040,
      "headline": "Economy Heating Up on PCE for June",
      "id": 136155105,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.",
      "url": "https://finnhub.io/api/news?id=1f9132f77d9ef9cec840390c58ca99a40eb0245409cda9055d2f96c3dd12d452"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion",
    "summary": "Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year. U.S. sales slipped 3% to $8.5 billion, while international revenues climbed 10% to $3.8 billion, representing an 8% increase when excluding foreign exchange impacts (Ex-FX). Growth Portfolio revenues of $6.6 billion increased 18%, or 17% Ex-FX. Revenue growth was primarily driven by the immuno-oncology (IO) portfolio, Breyanzi, Reblozy",
    "url": "https://finnhub.io/api/news?id=43cb093d3c203666ac453128cab28d7f4b381a05d94b3faf4889d30d8452d68e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753972945,
      "headline": "Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion",
      "id": 136155307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year. U.S. sales slipped 3% to $8.5 billion, while international revenues climbed 10% to $3.8 billion, representing an 8% increase when excluding foreign exchange impacts (Ex-FX). Growth Portfolio revenues of $6.6 billion increased 18%, or 17% Ex-FX. Revenue growth was primarily driven by the immuno-oncology (IO) portfolio, Breyanzi, Reblozy",
      "url": "https://finnhub.io/api/news?id=43cb093d3c203666ac453128cab28d7f4b381a05d94b3faf4889d30d8452d68e"
    }
  },
  {
    "ts": null,
    "headline": "Is Wall Street Bullish or Bearish on Bristol-Myers Stock?",
    "summary": "While Bristol-Myers Squibb has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=16a542428aec60e2213901a06229547747630a78aa9ab658fe9a6ca28982d9c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753970529,
      "headline": "Is Wall Street Bullish or Bearish on Bristol-Myers Stock?",
      "id": 136155308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "While Bristol-Myers Squibb has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=16a542428aec60e2213901a06229547747630a78aa9ab658fe9a6ca28982d9c8"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=65c0f0197d61a87c412736d0ba70250846f14ca56afb6bccc0143db803358916",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753968602,
      "headline": "Bristol Myers (BMY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 136155309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=65c0f0197d61a87c412736d0ba70250846f14ca56afb6bccc0143db803358916"
    }
  },
  {
    "ts": null,
    "headline": "Five Things That Might Move July 2025's Job Report",
    "summary": "July's jobs report reveals mixed signals. Discover key sectors with growth momentum and risks in labor trends to strategically position your portfolio.",
    "url": "https://finnhub.io/api/news?id=bf9966f57ad47866f0faa025eb017f7b67cc45162595361c4dfaf33069cdca8c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753965389,
      "headline": "Five Things That Might Move July 2025's Job Report",
      "id": 136154933,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1139664297/image_1139664297.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "July's jobs report reveals mixed signals. Discover key sectors with growth momentum and risks in labor trends to strategically position your portfolio.",
      "url": "https://finnhub.io/api/news?id=bf9966f57ad47866f0faa025eb017f7b67cc45162595361c4dfaf33069cdca8c"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.",
    "summary": "Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs expire in the coming years.",
    "url": "https://finnhub.io/api/news?id=0c363cd5e0cc19d375aafc9a014043be26a49969a1dd9fbe36ddb98629fafd91",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753964040,
      "headline": "Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.",
      "id": 136151945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs expire in the coming years.",
      "url": "https://finnhub.io/api/news?id=0c363cd5e0cc19d375aafc9a014043be26a49969a1dd9fbe36ddb98629fafd91"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates",
    "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of +36.45% and +7.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=e61ba105272c6f8523d999326f503ab8c763dcbb2f413bd8f6f1643f5d2bb8fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753963802,
      "headline": "Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates",
      "id": 136155310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of +36.45% and +7.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=e61ba105272c6f8523d999326f503ab8c763dcbb2f413bd8f6f1643f5d2bb8fd"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations",
    "summary": "Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.",
    "url": "https://finnhub.io/api/news?id=23d941fdcffdbf8ab9052ce2a3818ece51c7adcdd7a5d35474656be93bf190a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753963020,
      "headline": "Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations",
      "id": 136151946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.",
      "url": "https://finnhub.io/api/news?id=23d941fdcffdbf8ab9052ce2a3818ece51c7adcdd7a5d35474656be93bf190a2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio",
    "summary": "Investing.com -- Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across its Growth Portfolio, prompting the pharmaceutical giant to raise its full-year guidance. The stock rose 2.2% following the announcement.",
    "url": "https://finnhub.io/api/news?id=a0da462a3a41d6b25716d5c1566888c2f7799cf457f3bdbcfd9340db2b93008a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753962538,
      "headline": "Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio",
      "id": 136151947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com -- Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across its Growth Portfolio, prompting the pharmaceutical giant to raise its full-year guidance. The stock rose 2.2% following the announcement.",
      "url": "https://finnhub.io/api/news?id=a0da462a3a41d6b25716d5c1566888c2f7799cf457f3bdbcfd9340db2b93008a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: Q2 Earnings Snapshot",
    "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported second-quarter profit of $1.31 billion. On a per-share basis, the Princeton, New Jersey-based company said it had net income of 64 cents. Earnings, adjusted for non-recurring costs and amortization costs, were $1.46 per share.",
    "url": "https://finnhub.io/api/news?id=d3d4c50dea872af47ad293511c0ddfc772d8626e165bb0aa771b7e2b27ac7027",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753960731,
      "headline": "Bristol Myers: Q2 Earnings Snapshot",
      "id": 136151948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported second-quarter profit of $1.31 billion. On a per-share basis, the Princeton, New Jersey-based company said it had net income of 64 cents. Earnings, adjusted for non-recurring costs and amortization costs, were $1.46 per share.",
      "url": "https://finnhub.io/api/news?id=d3d4c50dea872af47ad293511c0ddfc772d8626e165bb0aa771b7e2b27ac7027"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers posts better-than-expected second quarter results on strength of top sellers",
    "summary": "(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its most established and best-selling brands, blood thinner Eliquis and cancer treatments Opdivo and Revlimid.  Shares of the drugmaker rose over 3% to $47.48 in premarket trading.  Revenue in the quarter, which analysts had expected to fall due to the loss of patent protection on some of its products, including Revlimid, rose 1% to $12.3 billion.",
    "url": "https://finnhub.io/api/news?id=a3f68cfaec8922a163d9b7f548e989fed4f73cb2a4fbbce4f1fa37360171b59d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753959673,
      "headline": "Bristol Myers posts better-than-expected second quarter results on strength of top sellers",
      "id": 136151949,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its most established and best-selling brands, blood thinner Eliquis and cancer treatments Opdivo and Revlimid.  Shares of the drugmaker rose over 3% to $47.48 in premarket trading.  Revenue in the quarter, which analysts had expected to fall due to the loss of patent protection on some of its products, including Revlimid, rose 1% to $12.3 billion.",
      "url": "https://finnhub.io/api/news?id=a3f68cfaec8922a163d9b7f548e989fed4f73cb2a4fbbce4f1fa37360171b59d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Reports Second Quarter Financial Results for 2025",
    "summary": "PRINCETON, N.J., July 31, 2025--Bristol Myers Squibb Reports Second Quarter Financial Results for 2025",
    "url": "https://finnhub.io/api/news?id=15124017fc8abc5e94eb8bb11d16e810f112a05cfda9970f5ed430c28f3eebfa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753959540,
      "headline": "Bristol Myers Squibb Reports Second Quarter Financial Results for 2025",
      "id": 136151950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., July 31, 2025--Bristol Myers Squibb Reports Second Quarter Financial Results for 2025",
      "url": "https://finnhub.io/api/news?id=15124017fc8abc5e94eb8bb11d16e810f112a05cfda9970f5ed430c28f3eebfa"
    }
  },
  {
    "ts": null,
    "headline": "US stock futures higher after Meta, Microsoft results",
    "summary": "Both companies are part of the so-called Magnificent Seven megacap, influential tech giants.",
    "url": "https://finnhub.io/api/news?id=b1aa538aaee4a91ec26531287d5aef70d39384d36b9b0d54f912b740b4160288",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753956724,
      "headline": "US stock futures higher after Meta, Microsoft results",
      "id": 136151598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Both companies are part of the so-called Magnificent Seven megacap, influential tech giants.",
      "url": "https://finnhub.io/api/news?id=b1aa538aaee4a91ec26531287d5aef70d39384d36b9b0d54f912b740b4160288"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company 2025 Q2 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q2 earnings call.",
    "url": "https://finnhub.io/api/news?id=cf41d23fb959f00145cc399f25984c151281b640ca9818e24ddfa3840bd47dc6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753956076,
      "headline": "Bristol-Myers Squibb Company 2025 Q2 - Results - Earnings Call Presentation",
      "id": 136152540,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q2 earnings call.",
      "url": "https://finnhub.io/api/news?id=cf41d23fb959f00145cc399f25984c151281b640ca9818e24ddfa3840bd47dc6"
    }
  },
  {
    "ts": null,
    "headline": "Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA",
    "summary": "Discover key insights with the \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" report. Gain an overview of global MS clinical trial landscapes, including data by region, phase, and sponsor. Identify top drugs and trial trends to optimize strategies. Enhance decision-making and competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial re",
    "url": "https://finnhub.io/api/news?id=f304a180423e033b5a2b7661e14cdb110733c435dcaf9533a22205491e1b0c7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954980,
      "headline": "Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA",
      "id": 136151856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Discover key insights with the \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" report. Gain an overview of global MS clinical trial landscapes, including data by region, phase, and sponsor. Identify top drugs and trial trends to optimize strategies. Enhance decision-making and competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Multiple Sclerosis - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial re",
      "url": "https://finnhub.io/api/news?id=f304a180423e033b5a2b7661e14cdb110733c435dcaf9533a22205491e1b0c7e"
    }
  },
  {
    "ts": null,
    "headline": "Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON",
    "summary": "Discover key insights in the \"Mycosis Fungoides - Global Clinical Trials Review, 2025.\" This comprehensive report covers global trial scenarios, detailing enrollment trends, regional data (G7 & E7), and prominent drugs. Leverage informed decision-making and strategic planning with the latest trial landscape analysis.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Mycosis Fungoides - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinic",
    "url": "https://finnhub.io/api/news?id=b1005680d0fa7c1ba1ae6f6256db21ea0421ec327bdb7a819910038b212a4c02",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753954260,
      "headline": "Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON",
      "id": 136151783,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Discover key insights in the \"Mycosis Fungoides - Global Clinical Trials Review, 2025.\" This comprehensive report covers global trial scenarios, detailing enrollment trends, regional data (G7 & E7), and prominent drugs. Leverage informed decision-making and strategic planning with the latest trial landscape analysis.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The \"Mycosis Fungoides - Global Clinical Trials Review, 2025\" clinical trials has been added to ResearchAndMarkets.com's offering.The clinic",
      "url": "https://finnhub.io/api/news?id=b1005680d0fa7c1ba1ae6f6256db21ea0421ec327bdb7a819910038b212a4c02"
    }
  },
  {
    "ts": null,
    "headline": "Apple and Amazon headline earnings slate",
    "summary": "Apple and Amazon headline earnings slate",
    "url": "https://finnhub.io/api/news?id=2de3a5546373fc10a35dd64f7067023aab991baba2ee4678b7916010f7eba160",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753939344,
      "headline": "Apple and Amazon headline earnings slate",
      "id": 136167654,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Apple and Amazon headline earnings slate",
      "url": "https://finnhub.io/api/news?id=2de3a5546373fc10a35dd64f7067023aab991baba2ee4678b7916010f7eba160"
    }
  }
]